Overview

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Status:
Active, not recruiting
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, active-controlled phase 3 study of ABP 959 in participants with paroxysmal nocturnal hemoglobinuria.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Eculizumab